- Home
- RY vs SNY Comparison
RY vs SNY Comparison
Compare RY & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RY
- SNY
- Stock Information
- Founded
- RY 1864
- SNY 1994
- Country
- RY Canada
- SNY France
- Employees
- RY N/A
- SNY N/A
- Industry
- RY
- SNY Biotechnology: Pharmaceutical Preparations
- Sector
- RY
- SNY Health Care
- Exchange
- RY Nasdaq
- SNY Nasdaq
- Market Cap
- RY 186.5B
- SNY 113.4B
- IPO Year
- RY N/A
- SNY N/A
- Fundamental
- Price
- RY $146.31
- SNY $47.16
- Analyst Decision
- RY Strong Buy
- SNY Buy
- Analyst Count
- RY 2
- SNY 4
- Target Price
- RY $177.50
- SNY $61.50
- AVG Volume (30 Days)
- RY 938.9K
- SNY 2.7M
- Earning Date
- RY 08-27-2025
- SNY 10-24-2025
- Dividend Yield
- RY 2.91%
- SNY 3.40%
- EPS Growth
- RY 18.99
- SNY 118.56
- EPS
- RY 9.55
- SNY 8.65
- Revenue
- RY $43,552,874,021.00
- SNY $53,714,621,258.00
- Revenue This Year
- RY $25.11
- SNY $1.53
- Revenue Next Year
- RY $3.05
- SNY $7.06
- P/E Ratio
- RY $15.31
- SNY $5.43
- Revenue Growth
- RY 16.26
- SNY 15.65
- 52 Week Low
- RY $106.10
- SNY $44.73
- 52 Week High
- RY $147.64
- SNY $60.12
- Technical
- Relative Strength Index (RSI)
- RY 69.33
- SNY 44.10
- Support Level
- RY $144.00
- SNY $46.50
- Resistance Level
- RY $146.95
- SNY $47.33
- Average True Range (ATR)
- RY 1.19
- SNY 0.66
- MACD
- RY -0.18
- SNY -0.13
- Stochastic Oscillator
- RY 77.60
- SNY 39.04
About RY Royal Bank Of Canada
Royal Bank of Canada is one of the two largest banks in Canada, with around CAD 2.2 trillion in assets. It is a diversified financial services company, offering personal and commercial banking, wealth management, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada and has dominant market shares. RBC also has wealth and capital market businesses in the US, UK, and other countries. RBC is a top 15 investment bank globally.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.